Balyasny Asset Management LLC Biocryst Pharmaceuticals Inc Transaction History

Balyasny Asset Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$4.98 - $6.77 $7.79 Million - $10.6 Million	1,563,289 Added 382.88%	1,971,586 $11.8 Million
Q3 2023 Nov 14, 2023	BUY	$6.71 - $7.92 $2.74 Million - $3.23 Million	408,297 New	408,297 $2.89 Million
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $315,175 - $432,600	29,210 Added 2.45%	1,223,721 $15.4 Million
Q2 2022 Aug 15, 2022	BUY	$7.89 - $17.88 $9.42 Million - $21.4 Million	1,194,511 New	1,194,511 $12.6 Million
Q2 2020 Aug 14, 2020	SELL	$1.9 - $5.61 $5.71 Million - $16.9 Million	-3,005,676 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.6 - $4.11 $4.81 Million - $12.4 Million	3,005,676 New	3,005,676 $6.01 Million
Q1 2018 May 15, 2018	SELL	$4.35 - $5.82 $48,245 - $64,549	-11,091 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$4.16 - $5.33 $177,652 - $227,617	-42,705 Reduced 79.38%	11,091 $54,000
Q3 2017 Nov 14, 2017	BUY	$4.1 - $5.97 $220,563 - $321,162	53,796	53,796 $282,000

279

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.